Literature DB >> 19182082

Would self-expanding stent occlude middle cerebral artery perforators?

Thomas W Leung1, Simon C H Yu, Wynnie W M Lam, Anne Y Y Chan, Alexander Y L Lau, Lawrence K S Wong.   

Abstract

BACKGROUND AND
PURPOSE: A major concern of intracranial stenting is perforator infarction. It is unclear whether the sustained radial force of a self-expanding stent or subsequent stent restenosis would cause late occlusion of perforators.
METHODS: We compared the baseline and poststent (>or=4 months) MRI scans of patients who underwent self-expanding stenting for recurrent ischemic symptoms attributed to a MCA stenosis >or=60%. New infarcts in the ipsilateral striatocapsular region were recorded.
RESULTS: MCA stenting was technically successful in 23 of 24 recruited patients. No new perforator territory infarct was found in follow-up MRI scans of all recruited patients. Postoperatively, all patients reported no further TIA or stroke over a median follow-up of 15 months.
CONCLUSIONS: The use of a self-expanding stent in patients with high-grade MCA stenosis may not pose a major risk to the perforators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182082     DOI: 10.1161/STROKEAHA.108.532416

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  14 in total

1.  Histopathologic description of Wingspan stent in acute ischemic stroke.

Authors:  Vivien H Lee; Susan Samuels; Thomas J Herbst; Marlene Gallegos; Elizabeth J Cochran; Michael Chen; Shyam Prabhakaran; Demetrius K Lopes
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

2.  Balloon-expandable stent placement in patients with immediate reocclusion after initial successful thrombolysis of acute middle cerebral arterial obstruction.

Authors:  H K Lee; H S Kwak; G H Chung; S B Hwang
Journal:  Interv Neuroradiol       Date:  2012-03-16       Impact factor: 1.610

Review 3.  MR angiography and imaging for the evaluation of middle cerebral artery atherosclerotic disease.

Authors:  A J Degnan; G Gallagher; Z Teng; J Lu; Q Liu; J H Gillard
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-22       Impact factor: 3.825

4.  Primary angioplasty for a subtype of symptomatic middle cerebral artery stenosis.

Authors:  Zhongrong Miao; Bin Wang; Lei Feng; Yang Hua; Feng Ling
Journal:  Neuroradiology       Date:  2010-10-08       Impact factor: 2.804

5.  Stenting versus medical treatment for severe symptomatic intracranial stenosis.

Authors:  C-W Tang; F-C Chang; C-M Chern; Y-C Lee; H-H Hu; I-H Lee
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

6.  Endovascular treatment of symptomatic intracranial atherosclerotic disease.

Authors:  Jody L Short; Arshad Majid; Syed I Hussain
Journal:  Front Neurol       Date:  2011-02-14       Impact factor: 4.003

7.  Solitaire AB stent-angioplasty for stenoses in perforator rich segments: A single-center experience.

Authors:  Xiangyu Cao; Jun Wang; Chenglin Tian; Zhihua Du; Hui Su; Xinfeng Liu; Bin Lv; Shengyuan Yu; Xing Chen; Ferdinand Hui
Journal:  Interv Neuroradiol       Date:  2020-08-25       Impact factor: 1.610

8.  Reappraisal of primary balloon angioplasty without stenting for patients with symptomatic middle cerebral artery stenosis.

Authors:  Hideo Okada; Tomoaki Terada; Yuko Tanaka; Nagatsuki Tomura; Kenichi Kono; Ryo Yoshimura; Aki Shintani
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-01-23       Impact factor: 1.742

9.  Learning curve of Wingspan stenting for intracranial atherosclerosis: single-center experience of 95 consecutive patients.

Authors:  Simon Chun Ho Yu; Thomas Wai Hong Leung; Kwok Tung Lee; Lawrence Ka Sing Wong
Journal:  J Neurointerv Surg       Date:  2013-03-20       Impact factor: 5.836

10.  Angioplasty and stenting of intracranial atherosclerosis with the Wingspan system: 1-year clinical and radiological outcome in a single Asian center.

Authors:  Simon Chun Ho Yu; Thomas Wai Hong Leung; Kwok Tung Lee; Lawrence Ka Sing Wong
Journal:  J Neurointerv Surg       Date:  2013-03-19       Impact factor: 5.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.